ArticleInternational journal of antimicrobial agents2016
Repurposing auranofin for the treatment of cutaneous staphylococcal infections.
Article in International journal of antimicrobial agents, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Efficacy of tenofovir on clinical outcomes of COVID-19 patients: a systematic review.BMC infectious diseases · 2025Pooled it
- Repurposing the angiotensin II receptor blocker valsartan to inhibit penicillin-binding protein 3 and its mutants inFrontiers in bioinformatics · 2026Article
- Article
- Antimicrobial and Antibiofilm Activity of Auranofin and Its Two Derivatives Bearing Naproxen and Acetylcysteine as Ligands Against Staphylococci.Antibiotics (Basel, Switzerland) · 2025Article
- Anti-inflammatory drugs as potential antimicrobial agents: a review.Frontiers in pharmacology · 2025Review
- The Many Lives of Auranofin: How an Old Anti-Rheumatic Agent May Become a Promising Antimicrobial Drug.Antibiotics (Basel, Switzerland) · 2024Review
- Gold Nanoclusters as Nanoantibiotic Auranofin Analogues.Advanced healthcare materials · 2022Article
- Anti-Staphylococcal Activity of the Auranofin Analogue Bearing Acetylcysteine in Place of the Thiosugar: An Experimental and Theoretical Investigation.Molecules (Basel, Switzerland) · 2022Article
- Auranofin exerts antibacterial activity against Neisseria gonorrhoeae in a female mouse model of genital tract infection.PloS one · 2022Article
- Identification of Promising Antifungal Drugs againstJournal of fungi (Basel, Switzerland) · 2021Article
- Metal Complexes as Antiviral Agents for SARS-CoV-2.Chembiochem : a European journal of chemical biology · 2021Review
- Investigating auranofin for the treatment of infected diabetic pressure ulcers in mice and dermal toxicity in pigs.Scientific reports · 2021Article
- Thioredoxin Reductase Is a Valid Target for Antimicrobial Therapeutic Development Against Gram-Positive Bacteria.Frontiers in microbiology · 2021Article
- Antimicrobial, Antibiofilm, and Anti-persister Activities of Penfluridol AgainstFrontiers in microbiology · 2021Article
- Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria.Theranostics · 2021Review
- Comparison of Proteomic Responses as Global Approach to Antibiotic Mechanism of Action Elucidation.Antimicrobial agents and chemotherapy · 2020Article
- Tree-Based QSAR Model for Drug Repurposing in the Discovery of New Antibacterial Compounds AgainstPharmaceuticals (Basel, Switzerland) · 2020Article
- Anti-virulence strategies forGut microbes · 2020Review
- Antimicrobial photodynamic activity of gallium-substituted haemoglobin on silver nanoparticles.Nanoscale · 2020Article
- Inhibiting the two-component system GraXRS with verteporfin to combat Staphylococcus aureus infections.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
The scourge of multidrug-resistant bacterial infections necessitates the urgent development of novel antimicrobials to address this public health challenge. Drug repurposing is a proven strategy to discover new antimicrobial agents; given that these agents have undergone extensive toxicological and pharmacological analysis, repurposing is an effective method to reduce the time, cost and risk associated with traditional antibiotic innovation. In this study, the in vitro and in vivo antibacterial activities of an antirheumatic drug, auranofin, was investigated against multidrug-resistant Staphylococcus aureus. The results indicated that auranofin possesses potent antibacterial activity against all tested strains of S. aureus, including meticillin-resistant S. aureus (MRSA), vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA), with minimum inhibitory concentrations (MICs) ranging from 0.0625μg/mL to 0.125μg/mL. In vivo, topical auranofin proved superior to conventional antimicrobials, including fusidic acid and mupirocin, in reducing the mean bacterial load in infected wounds in a murine model of MRSA skin infection. In addition to reducing the bacterial load, topical treatment of auranofin greatly reduced the production of inflammatory cytokines, including tumour necrosis factor-α (TNFα), interleukin-6 (IL-6), interleukin-1 beta (IL-1β) and monocyte chemoattractant protein-1 (MCP-1), in infected skin lesions. Moreover, auranofin significantly disrupted established in vitro biofilms of S. aureus and Staphylococcus epidermidis, more so than the traditional antimicrobials linezolid and vancomycin. Taken together, these results support that auranofin has potential to be repurposed as a topical antimicrobial agent for the treatment of staphylococcal skin and wound infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.